22 Jan Laminar Pharma awarded a 6,15M€ grant by the H2020 Programme to conduct a PIIb trial with 2OHOA in patients with newly-diagnosed glioblastoma
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Laminar Pharma and integrated by 12 leading clinical research institutions, Universities and SMEs...